您当前所在的位置:首页 > 产品中心 > 产品详细信息
537-46-2 分子结构
点击图片或这里关闭

methyl[(2S)-1-phenylpropan-2-yl]amine

ChemBase编号:1357
分子式:C10H15N
平均质量:149.2328
单一同位素质量:149.12044949
SMILES和InChIs

SMILES:
N([C@H](Cc1ccccc1)C)C
Canonical SMILES:
CN[C@H](Cc1ccccc1)C
InChI:
InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
InChIKey:
MYWUZJCMWCOHBA-VIFPVBQESA-N

引用这个纪录

CBID:1357 http://www.chembase.cn/molecule-1357.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
methyl[(2S)-1-phenylpropan-2-yl]amine
IUPAC传统名
methamphetamine
商标名
Desoxyn
Desyphed
Desyphed hydrochloride
Metamfetamine
Metamfetamine-m
Norodin
Speed
Stimulex
别名
(+ )-methylamphetamine
(+)-(s)-deoxyephedrine
(+)-(s)-n-alpha-dimethylphenethylamine
(+)-2-(N-Methylamino)-1-phenylpropane
(+)-methamphetamine
(+)-methylamphetamine
(+)-n,alpha-dimethyl-beta-phenylethylamine
(+)-n,alpha-dimethylphenethylamine
(+)-n-methylamphetamine
(2S)-N-methyl-1-phenylpropan-2-amine
(s)-(+)-deoxyephedrine
(s)-(+)-methamphetamine
(s)-(+)-n,alpha,dimethylphenethylamine
(s)-methamphetamine
(s)-methylamphetamine
(s)-n,alpha-dimethylbenzeneethanamine
(s)-n,alpha-dimethylbenzeneethanoamine
1-Phenyl-2-methylamino-propan [German]
1-Phenyl-2-methylaminopropane
2S-(+)-Methamphetamine
D-(s)-methamphetamine
D-1-Phenyl-2-methylaminopropane
d-1-Phenyl-2-methylaminopropan [German]
D-deoxyephedrine
D-methylamphetamine
D-methamphetamine
D-desoxyephedrine
D-n,alpha-dimethylphenethylamine
D-n-methylamphetamine
D-phenylisopropylmethylamine
Desoxyephedrine hydrochloride
L-methamphetamine
Metamfetamina [inn-spanish]
Metamfetaminum [inn-latin]
Metamphetamine
Metanfetamina [inn-spanish]
Methamphetaminum [inn-latin]
Methyl-beta-phenylisopropylamine
Methylamphetamine
N-Methyl-1-phenyl-2-propanamine
N-methyl-beta-phenylisopropylamin [german]
N-methyl-beta-phenylisopropylamine
N-methylamphetamine
S-(+)-methamphetamine
Ice
Meth
Methamphetamine
CAS号
537-46-2
PubChem SID
160964817
46508541
PubChem CID
10836

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
DrugBank DB01577 external link
PubChem 10836 external link
数据来源 数据ID 价格

理论计算性质

理论计算性质

JChem ALOGPS 2.1
质子受体 质子供体
LogD (pH = 5.5) -0.9906569  LogD (pH = 7.4) -0.43709657 
Log P 2.236831  摩尔折射率 48.4798 cm3
极化性 19.21153 Å3 极化表面积 12.03 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Log P 2.23  LOG S -2.21 
溶解度 9.28e-01 g/l 

分子性质

分子性质

理化性质 生物活性(PubChem)
疏水性(logP)
2.07 [HANSCH,C ET AL. (1995)] expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB01577 external link
Item Information
Drug Groups illicit; approved
Description Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.
Indication For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.
Pharmacology Methamphetamine is a potent central nervous system stimulant which affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. The acute effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite.
Toxicity Manifestations of acute overdosage with methamphetamine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine, with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine. Other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine.
Absorption Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.
Half Life The biological half-life has been reported in the range of 4 to 5 hours.
Elimination Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.
References
Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA: Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003 Jan;49(1):121-32. [Pubmed]
McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM: The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005 Sep;100(9):1320-9. [Pubmed]
Bennett BA, Hollingsworth CK, Martin RS, Harp JJ: Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998 Jan 26;782(1-2):219-27. [Pubmed]
Hasan AA, Ciancio S: Relationship between amphetamine ingestion and gingival enlargement. Pediatr Dent. 2004 Sep-Oct;26(5):396-400. [Pubmed]
Shaner JW: Caries associated with methamphetamine abuse. J Mich Dent Assoc. 2002 Sep;84(9):42-7. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA: Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003 Jan;49(1):121-32. Pubmed
  • McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM: The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005 Sep;100(9):1320-9. Pubmed
  • Bennett BA, Hollingsworth CK, Martin RS, Harp JJ: Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998 Jan 26;782(1-2):219-27. Pubmed
  • Hasan AA, Ciancio S: Relationship between amphetamine ingestion and gingival enlargement. Pediatr Dent. 2004 Sep-Oct;26(5):396-400. Pubmed
  • Shaner JW: Caries associated with methamphetamine abuse. J Mich Dent Assoc. 2002 Sep;84(9):42-7. Pubmed
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle